Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Lemonade Inc (LMND) Price & Performance

ADMA Biologics IncTrade
Lemonade IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Lemonade Inc — how do they compare? ADMA Biologics Inc trades at $9.79 (market cap $2.22B), while Lemonade Inc trades at $51.67 (market cap $4.09B). The key difference: Lemonade Inc is the larger of the two by market cap. Which is the better fit depends on your goals.

ADMALMND
Market Cap
$2.22B$4.09B
Sector
HealthFinancials
52-Week High
$20.38$96.57
52-Week Low
$7.60$47.38
Enterprise Value
$2.29B$3.95B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.

The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.

Lemonade Inc

Lemonade (LMND) trades at $51.21, down 2.79% in the past 24 hours, with a bearish technical signal indicated by moving averages and ADX. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 79% year-over-year, but remains unprofitable with a net income margin of -14.19%. Recent news highlights a CFO transition and expansion into new states, while the stock faces volatility amid mixed analyst sentiment.

The outlook for LMND hinges on achieving profitability, guided for Q4 2026, but high valuation (P/S of 4.1) and persistent losses pose risks. Opportunities include AI-driven growth and market expansion, yet investors face execution risks and competitive pressures in the insurance sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Lemonade Inc

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.

Read more on LMND